Article
Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.
PloS one - 1 Jan 2017
Brænne Ingrid, Zeng Lingyao, Willenborg Christina, Tragante Vinicius, Kessler Thorsten, Willer Cristen J, Laakso Markku, Wallentin Lars, Franks Paul W, Salomaa Veikko, Dehghan Abbas, Meitinger Thomas, Samani Nilesh J, Asselbergs Folkert W, Erdmann Jeanette, Schunkert Heribert
Abstract excerpt
Glatiramer acetate is used therapeutically in multiple sclerosis but also known for adverse effects including elevated coronary artery disease (CAD) risk. The mechanisms underlying the cardiovascular side effects of the medication are unclear. Here, we made use of the chromosomal variation in the genes that are known to be affected by glatiramer treatment. Focusing on genes and gene products reported by drug-gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.